Company intelligence / Profile preview
iCo Therapeutics
Vancouver, British Columbia, Canadaicotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
iCo Therapeutics focused on reprofiling and reformulating drugs with established clinical history for new indications. Its lead asset, iCo-007 (an antisense oligonucleotide targeting c-Raf kinase), completed Phase 1 in diabetic macular edema and entered a physician-sponsored Phase 2 trial. Bertilimumab/iCo-008 (a monoclonal antibody against eotaxin-1) has been studied in over 120 patients in allergy indications with signs of efficacy and good safety profile. The company also developed an oral amphotericin B delivery system for systemic fungal infections that completed preclinical studies.
- Therapeutic areas
- OphthalmologyImmunologyInfectious Diseases
- Modalities
- Antisense oligonucleotideMonoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
JDRF InternationalCanadian Pharmacy
Beyond the preview
Go deeper on iCo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCo Therapeutics.